Drug manufacturer Eli Lilly announced Tuesday that its flagship weight loss medication, Zepbound, is now available for patient use.
Tirzepatide, its active ingredient, had been approved by the US Food and Drug Administration as a treatment for type 2 diabetes called Mounjaro. Last month, the FDA approved it for use in chronic weight management, placing an official stamp of…